STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
An FDA advisory panel backed Grail’s multi-cancer blood test on benefit-risk questions; the agency has not made its approval decision.
TL;DR
- STAT reported that panel members voted 7–2, with one abstention, that Galleri’s benefits outweighed its risks for the proposed indication.
- NPR reported that the panel also split 6–4 on reasonable assurance of effectiveness and voted 10–0 on safety.
- The panel’s recommendation is nonbinding; FDA approval remains a separate decision.
STAT reported that FDA advisers endorsed Galleri on the benefit-risk question, with a 7–2 vote and one abstention. [1]
NPR reported separate votes of 10–0 on safety and 6–4 on effectiveness. The FDA’s meeting notice confirms that the panel was asked to discuss and vote on Grail’s premarket application. [2] [3]
The FDA says advisory committee recommendations are nonbinding. The vote was not an agency approval. [3]
Why it matters
The vote is a milestone for multi-cancer screening, while the split effectiveness vote and FDA’s final authority leave clinical and regulatory questions open.
Editor's note
Headline is verbatim from STAT. This report distinguishes the advisory committee vote from FDA approval and makes no screening recommendation.